Morrow Phuong Khanh 4
4 · CRISPR Therapeutics AG · Filed May 24, 2022
Insider Transaction Report
Form 4
Morrow Phuong Khanh
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-05-23+90,000→ 90,000 totalExercise: $54.71Exp: 2032-05-23→ Common Shares (90,000 underlying) - Award
Restricted Stock Units
2022-05-23+27,750→ 27,750 total→ Common Shares (27,750 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]This restricted stock unit award was granted on May 23, 2022 with respect to 27,750 Common Shares, with (i) one quarter of the shares vesting on May 23, 2023, (ii) one quarter of the shares vesting on May 23, 2024, (iii) one quarter of the shares vesting on May 23, 2025, and (iv) one quarter of the shares vesting on May 23, 2026.
- [F3]This option was granted on May 23, 2022 with respect to 90,000 Common Shares, with 25% of the shares vesting on May 23, 2023 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.